Stock Market News for October 9, 2026

At a glance

On October 9, 2026, Delta Air Lines reported September-quarter revenue of $20.2 billion and net income of $756 million (down 47%); GlobalFoundries unveiled its FDX Fusion FD‑SOI platform with manufacturing planned in Dresden in 2028; IonQ demonstrated a quantum interconnect making more than 1,000 connections per second; Glaukos reported Phase 4 trial superiority with a 3.6 mmHg incremental IOP reduction at Month 3.

Earnings and guidance

Delta Air Lines (DAL) announces September-quarter GAAP revenue of $20.2 billion, net income of $756 million (down 47% YoY) and diluted EPS of $1.15, with adjusted EPS of $1.72 and December-quarter adjusted revenue expectations provided.

Semiconductors and hardware

GlobalFoundries (GFS) unveiled its FDX Fusion FD‑SOI platform roadmap with manufacturing planned to begin in Dresden, Germany, in 2028 and first-generation digital performance targeting seven‑nanometer‑class and >2x density versus first‑generation FDX.

Credo Technology Group (CRDO) will showcase optical and copper connectivity products at the 2026 OCP Global Summit October 12–15, including an optical backplane with SENKO, active cables, optical transceivers and a Weaver memory connectivity demo.

Braiin (BRAI) to participate in an AI panel at the Maxim Growth Summit on October 13, 2026, where CEO Natraj Balasubramanian will discuss AI adoption, infrastructure needs and sector trends.

Quantum and AI infrastructure

IonQ (IONQ) demonstrates a quantum interconnect generating more than 1,000 entanglement connections per second between a trapped‑ion qubit and a silicon vacancy quantum memory in real‑world hardware testing.

AZIO AI (AZIO) signs its first Atlas One hosting agreement with Power Champion for an initial 10 MW of capacity, expecting approximately $90 million in capacity reservation charges over the 60‑month initial term and expansion rights to 50 MW.

Gorilla Technology Group (GRRR) signed a non‑binding LOI to acquire a U.S. data centre with ~6 MW current utility capacity and a local pathway to ~36 MW total site capacity, targeting completion by end‑November 2026.

Drug trials and clinical data

Glaukos (GKOS) announces positive Phase 4 randomized GLK‑101‑04 topline results: at Month 3 the combination of iDose TR with cataract surgery reduced mean diurnal IOP by 11.1 mmHg vs 7.4 mmHg for surgery alone, an incremental treatment effect of 3.6 mmHg (p<0.0001).

Mineralys Therapeutics (MLYS) presents new lorundrostat data showing 46% of Launch‑HTN participants reached recommended systolic BP targets and Week 12 office SBP <130 mmHg with 50 mg in the Phase 3 pivotal trial.

Alumis (ALMS) announces Phase 3 envudeucitinib results from the ONWARD program with Week 48 complete skin clearance of 54% and sustained improvements in scalp, itch and quality‑of‑life measures.

Seaport Therapeutics (SPTX) presents additional Phase 1 GlyphAgo pharmacokinetic data showing a 6.8‑fold increase in agomelatine bioavailability and 10‑fold lower exposure variability versus unmodified agomelatine.

Milestone Pharmaceuticals (MIST) enrolls its first European participant in the ReVeRA‑301 Phase 3 trial evaluating etripamil nasal spray for AFib‑RVR, with the randomized study targeting ~150 treated patient events.

Deals and divestitures

McEwen (MUX) Inc. signs a definitive agreement to sell Fuller and its 60% Paymaster interest to Discovery subsidiary Dome Mine for US$55 million (US$5 million cash + US$50 million in Discovery shares), subject to TSX approval for the share issuance.

Vivakor (VIVK) signs a non‑binding LOI to acquire Direct Midstream for a proposed $40 million, including a contemplated $10 million Vivakor investment at closing and remaining consideration in Series B instruments.

Financings and offerings

CollPlant Biotechnologies (CLGN) announces a definitive private placement expected to raise approximately $3.7 million via 989,301 ordinary shares or equivalents and warrants priced at $3.74 per share with immediately exercisable warrants.

bioAffinity Technologies (BIAF) closes a registered direct financing and concurrent private placement raising approximately $4 million in gross proceeds at an institutional price of $6.122 per common share (or $6.115 per pre‑funded warrant).

Mining and production

Aura Minerals (AUGO) reports preliminary record Q3 2026 production of 95,557 gold equivalent ounces, up 27% from Q2 2026 and 29% from Q3 2025, and nine‑month production of 253,131 gold equivalent ounces at current prices.

WISeQey (WQEY) (Quantisimo) signs a definitive business combination agreement with GigCapital8 to pursue a Nasdaq listing via Quantisimo Holding, implying approximately $666.1 million of equity value at $10.00 per share to WISeQey and SEALSQ upon closing.

IMC Rare Earths (IMC) reports that Block H drilling at Itarantim found a seven‑meter interval averaging 5,695 ppm total rare earth oxides starting two meters below surface, with a three‑meter subsection averaging 7,841 ppm.

Corporate actions and listings

SkinHealth Systems (SKIN) announces a 1‑for‑20 reverse stock split of Class A common stock effective October 14, 2026 at 12:00 a.m. ET, reducing outstanding shares from ~130.3 million to ~6.5 million based on the October 7 share count.